Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+early stage breast cancer

被引：0
|
作者：
O'Shaughnessy, Joyce
Oestreicher, Nina
Fulcher, Nicole
Tseng, Wan-Yu
Beeks, April
Moore, Julia
Lalla, Deepa
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P3-12-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-12-20
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Predictors of pathologic complete response in HER2 positive breast cancer patients treated with neoadjuvant targeted therapy
    Rosario, Mariela Huerta
    Sahoo, Sunati
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [2] Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials
    Hicks, Mellissa
    Macrae, Erin R.
    Abdel-Rasoul, Mahmoud
    Layman, Rachel
    Friedman, Susan
    Querry, Jenny
    Lustberg, Maryam
    Ramaswamy, Bhuvaneswari
    Mrozek, Ewa
    Shapiro, Charles
    Wesolowski, Robert
    [J]. ONCOLOGIST, 2015, 20 (04): : 337 - 343
  • [3] HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review
    Brown-Glaberman, Ursa
    Dayao, Zoneddy
    Royce, Melanie
    [J]. ONCOLOGY-NEW YORK, 2014, 28 (04): : 281 - 289
  • [4] Neoadjuvant Trastuzumab in HER2+early breast cancer patients - one clinic experience
    Petruzelka, L.
    Bielcikova, Z.
    Zimovjanova, M.
    Tesarova, P.
    Pribylova, J.
    Hejduk, K.
    Chloupkova, R.
    [J]. BREAST, 2017, 32 : S78 - S78
  • [5] HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
    Dent, Susan
    Oyan, Basak
    Honig, Amd
    Mano, Max
    Howell, Sacha
    [J]. CANCER TREATMENT REVIEWS, 2013, 39 (06) : 622 - 631
  • [6] Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
    Swain, Sandra M.
    Macharia, Harrison
    Cortes, Javier
    Dang, Chau
    Gianni, Luca
    Hurvitz, Sara A.
    Jackisch, Christian
    Schneeweiss, Andreas
    Slamon, Dennis
    Valagussa, Pinuccia
    du Toit, Yolande
    Heinzmann, Dominik
    Knott, Adam
    Song, Chunyan
    Cortazar, Patricia
    [J]. CANCERS, 2022, 14 (20)
  • [7] A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer.
    Bae, Soong June
    Yoon, Chang-Ik
    Park, So Eun
    Cha, Chi Hwan
    Kim, Dooreh
    Lee, Janghee
    Ahn, Sung Gwe
    Park, Hyung Seok
    Cho, Youngup
    Jeong, Joon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Loss of HER2 after neoadjuvant treatment of HER2+early breast cancer
    Morales, S.
    Gasol Cudos, A.
    Rodriguez Galindo, A.
    Velasco, A.
    Canosa Morales, C.
    Sanchez Guzman, D. -R.
    Mele Olive, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S51 - S51
  • [9] Implications of HER2-Targeted Therapy on Extent of Surgery for Early-Stage Breast Cancer
    Aziz, Hamza
    Marcom, P. Kelly
    Hwang, E. Shelley
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (05) : 1404 - 1405
  • [10] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    [J]. MEDICINE, 2021, 100 (44)
12345